Haleon’s (HLN) Buy Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reiterated their buy rating on shares of Haleon (LON:HLN) in a research note published on Monday,London Stock Exchange reports. Jefferies Financial Group currently has a GBX 450 price target on the stock.

Other equities research analysts also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft dropped their price objective on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Berenberg Bank boosted their target price on shares of Haleon from GBX 510 to GBX 512 and gave the stock a “buy” rating in a report on Thursday, March 19th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 407.

Haleon Stock Performance

Shares of LON:HLN opened at GBX 371.50 on Monday. The firm has a 50 day moving average of GBX 386.02 and a 200 day moving average of GBX 367.65. The company has a quick ratio of 0.93, a current ratio of 0.92 and a debt-to-equity ratio of 52.26. The company has a market capitalization of £33.09 billion, a price-to-earnings ratio of 20.08, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25. Haleon has a 52 week low of GBX 325.10 and a 52 week high of GBX 419.50.

Haleon (LON:HLN) last announced its earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 6.43% and a net margin of 12.59%. On average, sell-side analysts predict that Haleon will post 19.5033282 earnings per share for the current fiscal year.

Insider Transactions at Haleon

In other news, insider Brian McNamara sold 704,974 shares of the company’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of GBX 368, for a total transaction of £2,594,304.32. Corporate insiders own 0.02% of the company’s stock.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.